Objective:A study of pericardial effusions in individuals with dyspnea was conducted to evaluate the prevalence and aetiology. Study Design:Prospective/Observational Study Place and Duration: Multicenteric study conducted at DHQ Hospital Bagh AJK/ Federal Govt. Polyclinic Hospital Islamabad and DHQ Teaching Hospital Gujranwala Medical College, Gujranwala. Duration was six months from 1st Oct 2021 to 31st March 2022. Methods:There were 135 patients of both genders had ages 18-75 years were presented in this study. Patients with dyspnea were admitted to emergency department. After obtaining informed written consent, we compiled detailed demographic information on all enrolled patients.Pericardial effusion was detected in all cases using echocardiography.The causes of pericardial effusion have been studied." SPSS 22.0 was used to analyze the data. Results: There were 75 (55.6%) males and 60 (44.4%) females in this study. Mean age of the patients was 58.16±10.79 years and had mean BMI 23.9±10.45 kg/m2. Majority of the patients were illiterate 90 (66.7%) and 45 (33.3%) were literate. We found frequency of pericardial effusions among 26 (19.3%) cases. Majority were males 17 (65.4%) and 9 (34.6%) were females. Most common cause of pericardial effusions were neoplastic diseases 10 (38.5%), idiopathic found in 8 (30.8%) cases, 3 (11.4%) had uremia, bacterial infections in 2 (7.7%) cases, frequency of HIV cases was 2 (7.7%) and 1 (3.8%) had other causes. Among 26 patients of pericardial effusions, small size effusion found in 14 (53.8%) cases, moderate size in 8 (30.8%) cases and large size in 4 (15.4%) cases. Conclusion: According to this study,patients with unexplained dyspnea had an increased risk of developing pericardial effusion,. The most prevalent cause of pericardial effusion was a neoplastic disease. Keywords:Electrocardiogram, Causes, Pericardial Effusion, Frequency, Dyspnea

Objective: The purpose of this study was to calculate the incidence of in-stent restenosis in patients with DES and stent lengths higher than 30mm who presented to a tertiary care hospital. Study Design: A Cross-sectional study Place and Duration: This cross-sectional study was conducted at Department of Cardiology, Rashid Latif Medical College, Lahore in the duration from February, 2022 to July, 2022. Methods: There were 83 patients of coronary artery disease (CAD)were included. After obtaining written consent from participants, researchers collected information about their participants' ages, sexes, body mass indexes, and co-morbidities. Atherosclerosis risk variables were collected with baseline investigations and an echocardiography for ejection fraction determination. Imaging studies were reviewed by board-certified interventional cardiologists, who found evidence of ISR. Past angioplasty information and stent details were recorded. Results: In our study mean age of the presented cases was 54.13±7.44 years and mean BMI 25.2±13.87 kg/m2. Most common comorbidity was diabetes found in 25 (30.1%) followed by hypertension in 23 (27.7%) and dyslipidemia in 20 (24.1%) cases. We found that 40 (48.2%) patients were smokers. Mean LDL cholesterol of the patients was 68.6±1.97 mg/dl and mean uric acid was 6.2±2.35 mg/dl. Majority of the cases 45 (54.2%) had poor socio-economic status. We found that frequency of ISR was higher among cases of biomatrix stent 24 (28.9%), followed by Xience stent in 22 (26.5%) cases, Ultimaster stent in 19 (22.9%) and Xlimus stent in 18 (21.7%) cases after coronary angiograpghy. Our results showed that the stents longer than 30mm were associated with a higher incidence of In-Stent Restenosis (p=0.03). Conclusion: Based on the findings of this study, we came to the conclusion that a previous diagnosis of diabetes mellitus and a longer stent length are both significant risk factors for developing in-stent restenosis. In our research, we found that instances with biomatrix stents had a greater incidence of ISR. Keywords: CAD, Drug eluting stents (DES), Coronary angiography, In-Stent Restenosis

Objective: To assess the prevalence of contrast-induced nephropathy and its associated risk factors in patients undergoing multi-vessel percutaneous coronary intervention (PCI). Study Design: Observational/ Prospective study Place and Duration: Armed forces institute of cardiology & National Institute of heart diseases, Rawalpindi, during from the period September 2019 to Feb 2020. Methods: There were 112 patients of both genders with ages 18-75 years were presented in this study. Data on enrolled patients' age, gender, BMI, marital status and education level were collected after receiving written permission from each patient. This research included people who had undergone a percutaneous coronary intervention. Serum creatinine >0.5mg/dl from the baseline value was classified as contrast induced nephropathy. CIN-related risk factors were studied. Data was analyzed using SPSS 24.0. Results: The mean age of the patients was 51.6±9.53 years and had mean BMI 23.5±15.67 kg/m2. Majority were males 68 (60.7%) and 44 (39.3%) were females. There were 75 (66.96%) patients married and 55 (49.1%) patients were educated. Frequency of contrast induced nephropathy was among 25 (22.3%) cases. Most common risk factor of CIP was contrast volume 19 (76%) and hypertension found in 17 (68%) cases, followed by diabetes mellitus in 15 (60%) cases, age >65 years in 13 (52%) cases, CHF in 11 (44%) cases, smoking history in 9 (36%) cases and family history of CAD was 4 (16%). Conclusion: Patients undergoing PCI are at a considerable risk of developing contrast-induced nephropathy. Among the risk variables for CIN were anaemia (age >70 years), diabetes mellitus (contrast volume >150 ml), and heart failure. Keywords: Risk Factors, Contrast Induced Nephropathy, Percutaneous Coronary Intervention

Background: No-reflow is a serious complication that can occur during primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). No-reflow is a frequent event during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), and it may affect cardiac prognosis. Objectives: The main objective of the study is to find the effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Methods: This study was conducted at Ayub Teaching Hospital Abbottabad over a period of six months (1st January 2022 to 30th June 2022). A total of 130 patients who underwent primary PCI for AMI were included. The occurrence of no-reflow during the procedure was noted, and six-month mortality was recorded. Results: Of the 130 patients included in the study, 34 (26.2%) developed no-reflow during PPCI. The mean age of the patients was 58.5 ± 9.6 years, and 73.8% were male. The most common risk factors for AMI were hypertension (52.3%), smoking (45.4%), and diabetes (36.2%). There were no significant differences in baseline clinical and angiographic characteristics between patients with and without no-reflow. Conclusions: The occurrence of no-reflow during primary PCI for AMI is associated with a higher six-month mortality rate. Further research is needed to explore strategies to prevent or mitigate the occurrence of no-reflow during primary PCI for AMI. Keywords: AMI, No-reflow, Mortality, percutaneous coronary intervention (PCI)